Laboratorios Farmaceuticos RoviLABFF 93 ROC (Joel Greenblatt) % is 8.08% as of Mar. 2026, which is 69% below its 10-year median of 26.38. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 978 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 72.09% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Laboratorios Farmaceuticos Rovi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.08%.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % or its related term are showing as below:
LABFF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.11 Med: 26.38 Max: 61.74
Current: 27.67
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest ROC (Joel Greenblatt) % was 61.74%. The lowest was 10.11%. And the median was 26.38%.
LABFF's ROC (Joel Greenblatt) % is ranked better than 72.09% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.495
vs LABFF: 27.67
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 8.08% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a ROC (Joel Greenblatt) % of 8.08% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 69% below median its historical median of 26.38. Over the past decade, Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % has ranged from 10.11 to 61.74. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #273 out of 978 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % too high?
Laboratorios Farmaceuticos Rovi's current ROC (Joel Greenblatt) % of 8.08% is 69% below median its 10-year median of 26.38. Over the past 10 years, this metric has ranged from a low of 10.11 to a high of 61.74. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.50. Laboratorios Farmaceuticos Rovi's value of 8.08% is 29.7% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #273 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #273 out of 978 companies for ROC (Joel Greenblatt) %. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.50. Laboratorios Farmaceuticos Rovi's value of 8.08% is 29.7% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own ROC (Joel Greenblatt) % has ranged from 10.11 to 61.74 over the past decade. While the company's 10-year median is 26.38 vs. the industry median of 11.50, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.50, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current ROC (Joel Greenblatt) % of 8.08% is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current ROC (Joel Greenblatt) % is 8.08%, which is 69% below median its own 10-year median of 26.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current ROC (Joel Greenblatt) % of 8.08%. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is 8.08%, which is 69% below median its 10-year median of 26.38 and 29.7% below the Drug Manufacturers industry median of 11.50. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current ROC (Joel Greenblatt) % is 8.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
ROC (Joel Greenblatt) %: 8.08% (69% below median its 10-year median of 26.38)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 29.7% below the Drug Manufacturers median (#273 of 978)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
